biopharmaceutical
Spain and Latin American countries have an opportunity to take the lead in two small biotechnology sectors. Researchers from the University of Valencia (UV), working together with the IDICHUS Foundation, have studied the productive fabric of the Spanish biotechnology industry. Their conclusion is that Spain's food and plant sectors have more clout than those in English-speaking countries.
PHILADELPHIA -- November 16, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced new study results on INTUNIV? (guanfacine) Extended-Release Tablets published in the October Journal of Child and Adolescent Psychopharmacology.
PHILADELPHIA -- November 16, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced new study results on INTUNIV? (guanfacine) Extended-Release Tablets published in the October Journal of Child and Adolescent Psychopharmacology.
CAMBRIDGE, MA -- November 11, 2009 -- Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collabora
HONOLULU - October 29, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced new study results on INTUNIV? (guanfacine) Extended Release Tablets, a
HONOLULU -- October 29, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Defi
PHILADEPHIA -- July 22, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-daily Vyvanse® (lisdexamfetamine dimesylate) CII significantly reduced the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in chi
LA JOLLA, CA, July 21, 2009 -- -- Discoveries by Scripps Research Institute scientists have led to a promising new drug candidate -- the first in its class -- for patients with a genetic protein-misfolding disease. In results announced by the biopharmaceutical firm FoldRx Pharmaceuticals, Inc.
Hollywood, FL -- July 1, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced results from a Phase 3b study that found VYVANSE® (lisdexamfetamine dimesylate) CII demonstrated significant efficacy at 14 hours after administration during a simulated workplace environment study in adults with Attention Deficit Hyperactivity Disorder (ADHD).
Cambridge, MA ? May, 21, 2009 ? Agios Pharmaceuticals, the first biopharmaceutical company focused on discovering and developing novel cancer metabolism drugs, announced that the leading scientific journal Science has published a review article, "Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation," authored by two of its founders, Lewis C.
DENVER, Colorado and TUSTIN, Calif., April 21, 2009--Peregrine Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 6, 2009 - AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced findings from its novel human-in-mouse (HIM) cancer model system, in which AVEO successfully created invasive human tumors from primary human breast tissue that develop
